1 ANNEX, Regulation (EU) 2024/197

In forcesince 19 Oct 2023

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

(1)

the following entries are inserted following the order of the index numbers corresponding to each entry:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘015-204-00-5 | benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate | 479-100-5 | 577705-90-9 | Repr. 1B | H360F |

GHS08

Dgr

H360F’ | | |

‘015-205-00-0 | benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]bis[phenol] (1:1) | 278-305-5 | 75768-65-9 | Repr. 1B | H360F |

GHS08

Dgr

H360F’ | | |

‘015-206-00-6 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyl(diethylamino)diphenylphosphonium 4-[1,1,1,3,3,3-hexafluoro-2-(4-hydroxyphenyl)propan-2-yl]phenolate (1:1) | — | — | Repr. 1B | H360F |

GHS08

Dgr

H360F’ | | |

‘015-207-00-1 | reaction mass of 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol and benzyltriphenylphosphonium, salt with 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol (1:1) | — | — | Repr. 1B | H360F |

GHS08

Dgr

H360F’ | | |

‘015-208-00-7 | dimethyl propylphosphonate | 242-555-3 | 18755-43-6 |

Muta. 1B

Repr. 1B

H340

H360Df

GHS08

Dgr

H340

H360Df’

‘050-034-00-5 | dibutyltin maleate | 201-077-5 | 78-04-6 |

Muta. 2

Repr. 1B

Acute Tox. 2

Acute Tox. 4

STOT RE 1

Skin Corr. 1

Eye Dam. 1

H341

H360FD

H330

H302

H372 (immune system)

H314

H318

GHS08

GHS06

GHS05

Dgr

H341

H360FD

H330

H302

H372 (immune system)

H314

inhalation:

ATE = 0,317 mg/L (dusts or mists)

oral:

ATE = 510 mg/kg bw’

‘050-035-00-0 | dibutyltin oxide | 212-449-1 | 818-08-6 |

Muta. 2

Repr. 1B

Acute Tox. 3

STOT RE 1

Skin Irrit. 2

Eye Dam. 1

H341

H360FD

H301

H372 (immune system)

H315

H318

GHS08

GHS06

GHS05

Dgr

H341

H360FD

H301

H372 (immune system)

H315

H318

oral:

ATE = 170 mg/kg bw’

‘603-244-00-1 | reaction mass of 1-(2,3-epoxypropoxy)–2,2-bis ((2,3-epoxypropoxy)methyl) butane and 1-(2,3-epoxypropoxy)-2-((2,3-epoxypropoxy)methyl)-2-hydroxymethyl butane | — | — |

Muta. 2

Repr. 1B

H341

H360F

GHS08

Dgr

H341

H360F’

‘603-245-00-7 | 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bisethanol | 221-665-5 | 3179-89-3 | Skin Sens. 1 | H317 |

GHS07

Wng

H317’ | | |

‘603-246-00-2 | 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctan-1-ol | 211-477-1 | 647-42-7 |

STOT RE 2

Aquatic Chronic 1

H373 (teeth, bones)

H410

GHS08

GHS09

Wng

H373 (teeth, bones)

H410

M = 1’ |

‘604-099-00-7 | 4,4'-[2,2,2-trifluoro-1-(trifluoromethyl)ethylidene]diphenol; bisphenol AF | 216-036-7 | 1478-61-1 | Repr. 1B | H360F |

GHS08

Dgr

H360F’ | | |

‘604-100-00-0 | nonylphenol, branched and linear, ethoxylated (with average molecular weight ≤ 1540 g/mol) [includes ortho-, meta-, para- isomers or any combination thereof] |

500-315-8

500-024-6

500-045-0

500-209-1

248-762-5

243-816-4

248-291-5

—

230-770-5 248-743-1 247-555-7 248-293-6

—

and others

127087-87-0

9016-45-9

26027-38-3

68412-54-4

27986-36-3

20427-84-3

27176-93-8

1119449-38-5 7311-27-5 27942-27-4 26264-02-8 27177-05-5 14409-72-4 and others

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 10’

‘606-155-00-6 |

cinnamaldehyde; 3-phenylprop-2-enal;

cinnamic aldehyde; cinnamal; [1]

(2E)-3-phenylprop-2-enal [2]

203-213-9 [1] - [2] | 104-55-2 [1] 14371-10-9 [2] | Skin Sens. 1A | H317 |

GHS07

Wng

H317 | | Skin Sens. 1; H317: C ≥ 0,01 %’ |

‘607-766-00-0 | tetramethylene dimethacrylate | 218-218-1 | 2082-81-7 | Skin Sens. 1B | H317 |

GHS07

Wng

H317’ | | |

‘607-767-00-6 | 7,7,9(or 7,9,9)-trimethyl–4,13-dioxo–3,14-dioxa–5,12-diazahexadecane–1,16-diyl bismethacrylate | 276-957-5 | 72869-86-4 | Skin Sens. 1B | H317 |

GHS07

Wng

H317’ | | |

‘607-768-00-1 | 2,2'-ethylenedioxydiethyl dimethacrylate | 203-652-6 | 109-16-0 | Skin Sens. 1B | H317 |

GHS07

Wng

H317’ | | |

‘607-769-00-7 | bifenox (ISO); methyl 5-(2,4-dichlorophenoxy)-2-nitrobenzoate | 255-894-7 | 42576-02-3 |

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

oral:

ATE = 1500 mg/kg bw

M = 1000

M = 1000’

‘612-295-00-9 | benfluralin (ISO); N-butyl-N-ethyl-α,α,α-trifluoro-2,6-dinitro-p-toluidine | 217-465-2 | 1861-40-1 |

Carc. 2

Repr. 2

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H361d

H315

H319

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H361d

H315

H319

H317

H410

M = 10

M = 10’

‘612-296-00-4 | N,N-dimethyl-p-toluidine | 202-805-4 | 99-97-8 |

Carc. 1B

Acute Tox. 4

Acute Tox. 3

STOT RE 2

Aquatic Chronic 3

H350

H332

H301

H373 (blood system, respiratory tract)

H412

GHS08

GHS06

Dgr

H350

H332

H301

H373 (blood system, respiratory tract)

H412

inhalation:

ATE = 1,4 mg/L (dusts or mists)

oral:

ATE = 140 mg/kg bw’

‘612-297-00-X | 1-phenylethan-1-one (1-phenylethylidene)hydrazone | 211-979-0 | 729-43-1 | Skin Sens. 1 | H317 |

GHS07

Wng

H317’ | | |

‘612-298-00-5 | 1,4-Benzenediamine, N,N’-mixed Ph and tolyl derivs.; | 273-227-8 | 68953-84-4 |

Repr. 1B

Skin Sens. 1

H360FD

H317

GHS08

GHS07

Dgr

H360FD

H317’

‘613-346-00-8 | 4-nitrosomorpholine | — | 59-89-2 |

Carc. 1B

Muta. 2

STOT RE 1

H350

H341

H372 (liver)

GHS08

Dgr

H350

H341

H372 (liver)

Carc. 1B; H350: C ≥ 0,001 %’ |

‘613-347-00-3 | difenoconazole (ISO); 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl–1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole; 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-2-yl]phenyl 4-chlorophenyl ether | — | 119446-68-3 |

Carc. 2

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H319

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H319

H410

oral:

ATE = 1450 mg/kg bw

M = 10

M = 10’

‘613-348-00-9 | 9-[2-(ethoxycarbonyl)phenyl]–3,6-bis(ethylamino)–2,7-dimethylxanthylium chloride; Basic Red 1 | 213-584-9 | 989-38-8 |

Acute Tox. 3

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H301

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H301

H318

H317

H410

oral:

ATE = 280 mg/kg bw

M = 10

M = 1’

‘613-349-00-4 | 4-methylimidazole | 212-497-3 | 822-36-6 |

Carc. 1B

Repr. 1B

H350

H360Fd

GHS08

Dgr

H350

H360Fd’

‘615-051-00-X | 3,3'-dimethylbiphenyl–4,4'-diyl diisocyanate | 202-112-7 | 91-97-4 |

Carc. 2

Resp. Sens. 1

Skin Sens. 1A

H351

H334

H317

GHS08

Dgr

H351

H334

H317

Skin Sens. 1A; H317: C ≥ 0,001 %’ |

‘616-241-00-5 | foramsulfuron (ISO); 2-{[(4,6-dimethoxypyrimidin-2-yl)carbamoyl]sulfamoyl}-4-formamido-N,N-dimethylbenzamide; 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-dimethylcarbamoyl-5-formamidophenylsulfonyl)urea | — | 173159-57-4 |

Carc. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H400

H410

GHS08

GHS09

Wng

H351

H410

M = 1000

M = 100’

‘616-242-00-0 | picolinafen (ISO); N-(4-fluorophenyl)-6-[3-(trifluoromethyl)phenoxy]pyridine-2-carboxamide; 4′-fluoro-6-[(α,α,α-trifluoro-m-tolyl)oxy]picolinanilide | — | 137641-05-5 |

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H373 (blood system, thyroid)

H400

H410

GHS08

GHS09

Wng

H373 (blood system, thyroid)

H410

M = 1000

M = 1000’

(2)

the entries corresponding to index numbers 006-015-00-9; 015-203-00-X; 016-001-00-4; 016-011-00-9; 017-004-00-3; 017-005-00-9; 082-013-00-1; 082-014-00-7; 603-057-00-5; 604-010-00-1; 604-074-00-0; 606-034-00-8; 607-032-00-X; 607-034-00-0; 607-223-00-8; 607-246-00-3; 612-004-00-5; 612-049-00-0; 612-056-00-9; 613-088-00-6; 613-127-00-7; 613-307-00-5; 616-035-00-5; 616-104-00-X are replaced by the following entries respectively:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘006-015-00-9 | diuron (ISO); 3-(3,4-dichlorophenyl)–1,1-dimethylurea | 206-354-4 | 330-54-1 |

Carc. 1B

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H350

H373 (blood system)

H400

H410

GHS08

GHS09

Dgr

H350

H373 (blood system)

H410

M = 100

M = 100’

‘015-203-00-X | diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide | 278-355-8 | 75980-60-8 |

Repr. 1B

Skin Sens. 1B

H360Fd

H317

GHS08

GHS07

Dgr

H360Fd

H317’

‘016-001-00-4 | hydrogen sulphide, hydrogen sulfide | 231-977-3 | 7783-06-4 |

Flam. Gas 1A

Press. Gas

Acute Tox. 2

Aquatic Acute 1

H220

H330

H400

GHS02

GHS06

GHS09

Dgr

H220

H330

H400

inhalation: ATE = 440 ppmV (gases) | U’

‘016-011-00-9 | sulphur dioxide; sulfur dioxide | 231-195-2 | 7446-09-5 |

Press. Gas

Acute Tox. 3

STOT SE 1

Skin. Corr. 1B

H331

H370 (respiratory system) (inhalation)

H314

GHS04

GHS06

GHS08

GHS05

Dgr

H331

H370 (respiratory system) (inhalation)

H314

inhalation: ATE = 1000 ppmV (gases) | U, 5’

‘017-004-00-3 | potassium chlorate | 223-289-7 | 3811-04-9 |

Ox. Sol. 1

Acute Tox. 3

H271

H301

GHS03

GHS06

Dgr

H271

H301

oral: ATE = 100 mg/kg bw’ |

‘017-005-00-9 | sodium chlorate | 231-887-4 | 7775-09-9 |

Ox. Sol. 1

Acute Tox. 3

H271

H301

GHS03

GHS06

Dgr

H271

H301

oral: ATE = 100 mg/kg bw’ |

‘082-013-00-1 |

lead powder;

[particle diameter < 1 mm]

231-100-4 | 7439-92-1 |

Repr. 1A

Lact.

Aquatic Acute 1

Aquatic Chronic 1

H360FD

H362

H400

H410

GHS08

GHS09

Dgr

H360FD

H362

H410

Repr. 1A;

H360D: C ≥ 0,03 %

M = 10

M = 100’

‘082-014-00-7 |

lead massive:

[particle diameter ≥ 1 mm]

231-100-4 | 7439-92-1 |

Repr. 1A

Lact.

Aquatic Chronic 1

H360FD

H362

H410

GHS08

GHS09

Dgr

H360FD

H362

H410

M = 10’ |

‘603-057-00-5 | benzyl alcohol | 202-859-9 | 100-51-6 |

Acute Tox. 4

Eye Irrit. 2

Skin Sens. 1B

H302

H319

H317

GHS07

Wng

H302

H319

H317

oral: ATE = 1200 mg/kg bw’ |

‘604-010-00-1 | resorcinol; 1,3-benzenediol | 203-585-2 | 108-46-3 |

Acute Tox. 4

STOT SE 1

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1B

Aquatic Acute 1

H302

H370 (nervous system)

H315

H319

H317

H400

GHS07

GHS08

GHS09

Dgr

H302

H370 (nervous system)

H315

H319

H317

H400

oral: ATE = 500 mg/kg bw

M = 1’

‘604-074-00-0 | 2,2',6,6'-tetrabromo–4,4'-isopropylidenediphenol; tetrabromobisphenol-A | 201-236-9 | 79-94-7 |

Carc. 1B

Aquatic Acute 1

Aquatic Chronic 1

H350

H400

H410

GHS08

GHS09

Dgr

H350

H410’

‘606-034-00-8 | metribuzin (ISO); 4-amino-6-tert-butyl-3-methylthio-1,2,4-triazin-5(4H)-one; 4-amino-4,5-dihydro-6-(1,1-dimethylethyl)-3-methylthio-1,2,4-triazin-5-one | 244-209-7 | 21087-64-9 |

Acute Tox. 4

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H302

H373 (blood system)

H400

H410

GHS07

GHS08

GHS09

Wng

H302

H373 (blood system)

H410

oral: ATE = 320 mg/kg bw

M = 10

M = 10’

‘607-032-00-X | ethyl acrylate | 205-438-8 | 140-88-5 |

Flam. Liq. 2

Acute Tox. 3

Acute Tox. 4

Acute Tox. 4

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

H225

H331

H312

H302

H335

H315

H319

H317

GHS02

GHS06

Dgr

H225

H331

H312

H302

H335

H315

H319

H317

inhalation: ATE = 9 mg/L (vapours)

dermal: ATE = 1800 mg/kg bw

oral: ATE = 1120 mg/kg bw

STOT SE 3; H335: C ≥ 5 %

Skin Irrit. 2; H315: C ≥ 5 %

Eye Irrit. 2; H319: C ≥ 5 %

D’

‘607-034-00-0 |

methyl acrylate;

methyl propenoate

202-500-6 | 96-33-3 |

Flam. Liq. 2

Acute Tox. 3

Acute Tox. 4

Acute Tox. 4

STOT SE 3

Skin Irrit. 2

Eye Irrit. 2

Skin Sens. 1

H225

H331

H312

H302

H335

H315

H319

H317

GHS02

GHS06

Dgr

H225

H331

H312

H302

H335

H315

H319

H317

inhalation: ATE = 3 mg/L (vapours)

dermal: ATE = 1100 mg/kg bw

oral: ATE = 500 mg/kg bw

D’

‘607-223-00-8 | transfluthrin (ISO); 2,3,5,6-tetrafluorobenzyl (1R,3S)-3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate | 405-060-5 | 118712-89-3 |

Carc. 2

Acute Tox. 4

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H302

H370 (nervous system)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H302

H370 (nervous system)

H410

EUH066 |

oral: ATE = 580 mg/kg bw

M = 1000

M = 1000’

‘607-246-00-3 |

allyl methacrylate;

2-methyl-2-propenoic acid 2-propenyl ester

202-473-0 | 96-05-9 |

Flam. Liq. 3

Acute Tox. 2

Acute Tox. 3

Acute Tox. 4

Aquatic Acute 1

H226

H330

H311

H302

H400

GHS02

GHS06

GHS09

Dgr

H226

H330

H311

H302

H400

inhalation: ATE = 1,5 mg/L (vapours)

dermal: ATE = 300 mg/kg bw

oral: ATE = 400 mg/kg bw’

‘612-004-00-5 | triethylamine | 204-469-4 | 121-44-8 |

Flam. Liq. 2

Acute Tox. 3

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1A

Eye Dam. 1

H225

H331

H311

H301

H314

H318

GHS02

GHS06

GHS05

Dgr

H225

H331

H311

H301

H314

inhalation: ATE = 7,2 mg/L (vapours)

dermal: ATE = 300 mg/kg bw

oral: ATE = 100 mg/kg bw STOT SE 3; H335: C ≥ 1 %’

‘612-049-00-0 | di-n-butylamine | 203-921-8 | 111-92-2 |

Flam. Liq. 3

Acute Tox. 2

Acute Tox. 3

Acute Tox. 3

Skin Corr. 1B

Eye Dam. 1

H226

H330

H311

H301

H314

H318

GHS02

GHS06

GHS05

Dgr

H226

H330

H311

H301

H314

EUH 071 |

inhalation: ATE = 1,2 mg/L (vapours) dermal: ATE = 300 mg/kg bw

oral: ATE = 220 mg/kg bw’

‘612-056-00-9 |

N,N-dimethyl-m-toluidine; [1]

N,N-dimethyl-o-toluidine [2]

204-495-6 [1] 210-199-8 [2] | 121-72-2 [1] 609-72-3 [2] | Acute Tox. 3 * Acute Tox. 3 * Acute Tox. 3 * STOT RE 2 * Aquatic Chronic 3 |

H331

H311

H301

H373 **

H412

GHS06 GHS08

Dgr

H331

H311

H301

H373 **

H412

* | C’

‘613-088-00-6 | 1,2-benzisothiazol-3(2H)-one; 1,2-benzisothiazolin-3-one | 220-120-9 | 2634-33-5 |

Acute Tox. 2

Acute Tox. 4

Skin Irrit. 2

Eye Dam. 1

Skin Sens. 1A

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H315

H318

H317

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H315

H318

H317

H410

inhalation:

ATE = 0,21 mg/L (dusts or mists)

oral: ATE = 450 mg/kg bw

Skin Sens. 1A; H317: C ≥ 0,036 %

M = 1

M = 1’

‘613-127-00-7 | mepiquat chloride (ISO); 1,1-dimethylpiperidinium chloride | 246-147-6 | 24307-26-4 |

Acute Tox. 4

Acute Tox. 3

Aquatic Chronic 3

H332

H301

H412

GHS06

Dgr

H332

H301

H412

inhalation: ATE = 2,8 mg/L (dusts or mists)

oral:

ATE = 270 mg/kg bw’

‘613-307-00-5 | clothianidin (ISO); (E)-1-(2-chloro–1,3-thiazol-5-ylmethyl)-3-methyl-2-nitroguanidine | 433-460-1 | 210880-92-5 |

Repr. 2

Acute Tox. 4

STOT SE 1

Aquatic Acute 1

Aquatic Chronic 1

H361f

H302

H370 (nervous system)

H400

H410

GHS08

GHS07

GHS09

Dgr

H361f

H302

H370 (nervous system)

H410

oral: ATE = 390 mg/kg bw

M = 10

M = 100’

‘616-035-00-5 |

cymoxanil (ISO); 2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [1]

(2E)-2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide; [2]

261-043-0 [1]

–

[2]

57966-95-7 [1]

166900-80-7 [2]

Repr. 2

Acute Tox. 4

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H302

H373 (blood system, thymus, eyes)

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H361fd

H302

H373 (blood system, thymus, eyes)

H317

H410

oral: ATE = 360 mg/kg bw

M = 1

M = 1’

‘616-104-00-X | benalaxyl (ISO); methyl N-(2,6-dimethylphenyl)-N-(phenylacetyl)-DL-alaninate | 275-728-7 | 71626-11-4 |

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

oral: ATE = 1000 mg/kg bw

M = 1

M = 1’